BofA raised the firm’s price target on Gilead (GILD) to $116 from $109 and keeps a Buy rating on the shares. Q4 results “handily beat ...

Ideaya Biosciences (IDYA) announced it has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences ...

According to preliminary data, the S&P 500 lost 16.58 points, or 0.28%, to end at 6,051.92 points, while the Nasdaq Composite ...

Asian shares mostly rose Wednesday, as regional markets continued to watch President Donald Trump’s latest tariff escalation ...

Gilead said its fourth-quarter HIV product sales rose to $5.45 billion from $4.69 billion a year earlier, due to higher ...

The head of the U.N. AIDS agency says the number of new HIV infections could jump more than six times by 2029 if American ...

Salesforce has announced a new CFO+ with an expanded set of responsibilities as a company veteran who "bleeds CRM" prepares ...